Should you start a weight management clinic?
The regulatory content is addressed elsewhere in this library, in the verification duties, the remote prescribing standards and the two-registration structure. This guide assumes that material and addresses the build.
It should nonetheless begin with the question owners skip. The category carries the heaviest scrutiny in private pharmacy. The entry test is not whether demand exists — it plainly does. It is whether the pharmacy can operate genuine verification and genuine monitoring at the volume it intends to reach, with a prescriber who can genuinely decline.
That threshold is deliberately awkward: a service that cannot meet it will fail in a way that damages more than the service. It is also now written down. The regulator's themed review of 24 April 2026 sets out six recommended actions. They cover risk assessment, due diligence on third party prescribing services, independent verification, individual clinical suitability with specific regard to vulnerable groups including those with eating disorders, thorough documentation and ongoing follow up. The inspection framework published on 13 January 2026 makes failure to verify weight, height or BMI an inspection failure. Both are set out in the verification duties article, and a build plan that does not answer all six is not a build plan. A pharmacy whose weight management arm attracts regulatory attention has a problem across its whole registration — and, as the payments material sets out, across its acquiring relationships too. An owner who cannot answer the entry test affirmatively should not proceed. The honest version of that answer sometimes arrives only after modelling the costs below.
What are the four structural choices?
Four decisions determine cost, control and reversibility, and each is considerably easier to make than to unmake.
| Choice | Options | What it determines |
|---|---|---|
| Prescribing capacity | Employed prescriber, contracted prescriber, partner clinic, or pharmacist prescriber in-house | Fixed versus variable cost, clinical control, continuity, and whether capacity scales with demand |
| Consultation model | In-person, remote asynchronous with synchronous escalation, or hybrid | Premises requirements, geographic reach, verification difficulty and the standards which apply |
| Corporate structure | Single registered pharmacy, or separate clinic entity alongside the pharmacy | Regulatory footprint, prescriber independence, and how the arrangement reads to underwriters and purchasers |
| Supply arrangement | Own stock, wholesaler account with buffer, or supply via partner | Working capital, exposure to shortage, and control over continuity of treatment |
The choice owners underestimate is the first. Contracted prescribing converts a fixed cost into a variable one, and it is the obvious route at low volume. But it also places the clinical decision, the availability and the escalation response outside the business. Where a service grows, that arrangement is frequently the constraint rather than the enabler. Renegotiating it under demand pressure is a poor position to negotiate from.
What does it cost to set up?
Published figures for this are unreliable, because they conflate very different models. The honest approach is to build the estimate from components. Five are unavoidable.
Prescriber capacity, whether as salary, sessional rates or a contracted arrangement. This is normally the largest single line, and the one that scales with volume.
The consultation and record system, capable of holding the questionnaire, the verification artefacts, the prescriber's reasoning and the review intervals in one place. This is the evidence pack the frameworks expect. A service running on forms and email will discover that at the least convenient moment.
Verification arrangements: the independent confirmation the category requires, rather than self-report. It can run through records requests, GP correspondence, in-person measurement or a verification provider.
Clinical governance: the protocols, the escalation policy, the audit schedule and the documentation an inspector would read.
Supply: initial stock or the arrangement replacing it, including cold chain where the product requires it.
Two further lines are commonly omitted and should not be. Staff time to operate the service, which is real capacity taken from an already stretched team. And the period before revenue, because a service takes months to build a cohort large enough to matter.
What order do you build it in?
Services fail in a predictable order, and it is the reverse of the order they are built in. The natural instinct is to start with the thing that produces revenue — the landing page, the pricing, the advertising — then add the consultation, then arrange a prescriber, and formalise the governance last because it produces nothing. That sequence guarantees the failure, because each layer constrains the one beneath it. A funnel built before the clinical protocol will ask the wrong questions. A consultation designed before the prescriber is appointed will not match how that prescriber works. A verification step added after launch has to be retrofitted into a flow patients are already using — and every existing patient has been assessed without it. The correct sequence is governance and protocol, then prescriber arrangements, then the consultation and record system, then verification workflows, then supply, then pricing, and promotion last. It feels slower and it is not. The alternative is a launch that stalls at the first serious question from an acquirer, a certifier or an inspector. At that point the rebuild happens anyway, under time pressure, with patients already in treatment.
How do you find a prescriber?
This is the practical bottleneck for most pharmacies. The question is less about finding one than about defining the relationship properly.
Four points determine whether the arrangement works. Independence must be genuine and structural: the prescriber's decision cannot be influenced by the service's commercial interest, and you should be able to describe the arrangement to a regulator without discomfort. Capacity must match intended volume, including the escalation and review workload rather than only initial consultations, because reviews accumulate as the cohort grows. Availability must cover escalation, so a flagged case reaches a human within a defined period rather than when the prescriber next logs in. And the contract should address what happens when the prescriber declines. A service whose economics depend on approval rates has created exactly the pressure the frameworks exist to prevent.
The recruitment reality: good prescribers assess the pharmacy as carefully as the pharmacy assesses them. The services that attract them are the ones with proper protocols, working records and a realistic view of caseload. Governance built first is therefore also a recruitment asset — an argument for the sequence above beyond compliance.
How should the service be priced?
Against the cost of delivering it properly, rather than against the comparison sites, and per month of supply collected as supplied rather than as an upfront course.
The category's pricing dynamic is set out in the oral GLP-1 analysis, and the conclusion carries directly. Product margin is competed away; the service layer is where a defensible position exists. A price that covers only the medicine plus a thin margin has priced the monitoring at zero, and will fund it out of goodwill until goodwill runs out.
Three principles follow. The review is part of the price and should never be discounted to the point where it reads as a formality. It is simultaneously the safety mechanism and the retention mechanism. Introductory offers are acquisition spend and should be modelled against the actual retention curve, not adopted because competitors use them. And the exit should be clean. Patients who can stop easily return more often than those who had to fight a cancellation process, and the alternative generates the disputes the consumer law guide describes.
What does the service look like at month eighteen?
Business cases model month three. The service is decided at month eighteen, and it looks materially different from the launch.
By then the cohort is mostly established rather than new, which inverts the workload. Reviews, monitoring, side-effect management, dose changes and discontinuation conversations exceed new consultations. A staffing model built around acquisition is now mismatched to the work. Patients on maintenance ask different questions from patients starting. Some have plateaued and want to know why. Some want to stop and need that handled properly. Some have been lost to follow-up and should be recalled rather than quietly forgotten.
Two consequences deserve planning for at the outset. Prescriber capacity must scale with the cohort rather than with new starts — the arithmetic contracted arrangements most often fail to accommodate. And retention is the whole economics. The measure that matters is the proportion still in treatment and still paying at month twelve and beyond, not conversion rate on the landing page.
A pharmacy that has modelled month eighteen honestly will build a smaller launch and a more durable service. That is close to the opposite of what the category's marketing encourages.
Where should you not economise?
Four lines, each tempting to reduce and expensive to have reduced.
Verification. The category's defining failure is accepting self-reported measurements. A service that economises here has built the thing regulators are looking for.
The record system. Evidencing a decision two years later is the difference between an audit and an investigation. A service running on spreadsheets and inboxes cannot do it.
Prescriber time. Buying the minimum capacity produces the throughput pattern regulators have publicly criticised. The saving is small relative to what it risks.
The decline pathway. Handling refusals well costs something and returns more: refused patients talk, review and return. A refusal rate approaching zero is itself the warning.
When should you stop?
A build should define in advance what would cause it to be abandoned. The decision is far harder once patients are enrolled and money is spent.
Four criteria are worth writing down before launch. If prescriber capacity cannot be secured on terms that preserve genuine independence, the service should not open. If verification cannot be operated at the intended volume, the volume should reduce or the service should not proceed. If the price required to fund proper monitoring cannot be achieved in the market the pharmacy serves, the model does not work regardless of demand. And if retention at month twelve falls materially below the level the business case required, the service should be reduced or closed rather than sustained by increasing acquisition spend.
Writing those down is unglamorous, and it is the difference between a considered exit and a slow one. In this category particularly, it is also the mark of an operator who has understood what they are entering.
Key takeaways
- The entry test is not whether demand exists but whether genuine verification and monitoring can be operated at the intended volume with a prescriber who can genuinely decline.
- Four structural choices determine everything downstream: prescribing capacity, consultation model, corporate structure and supply arrangement. Each is easier to make than to unmake.
- Build the cost estimate from five unavoidable components rather than a headline figure. Include staff time and the pre-revenue period, which are routinely omitted.
- Build governance and protocol first and promotion last. Every layer constrains the one beneath it, and retrofitting verification into a live flow means existing patients were assessed without it.
- Price against the cost of delivering the service properly, not against comparison sites. Product margin is competed away, and the review is both the safety and the retention mechanism.
- Model month eighteen rather than month three. Reviews and monitoring will exceed new consultations, and prescriber capacity must scale with the cohort rather than with new starts.
- Do not economise on verification, records, prescriber time or the decline pathway. Write down the kill criteria before launch, not after enrolment.
Sources and further reading
FAQs
Governance first, funnel last.
The record system is the component this guide says not to economise on. Evidencing a decision two years later is the difference between an audit and an investigation. Dataforge PMR holds the questionnaire, the verification artefacts, the prescriber's reasoning and the review intervals on one patient journey, and fires the recalls a maturing cohort depends on.
See Dataforge PMR